argenx to Speak at Goldman Sachs 45th Annual Global Healthcare Conference

Argenx, a prominent global immunology company headquartered in Amsterdam, the Netherlands, has announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. This event is scheduled to take place on Tuesday, June 11, 2024, at 2:40 PM ET in Miami, FL. Members of the company's management team will engage in a fireside chat during the conference.

For those interested in the live discussion, a webcast will be made available through the Investors section of the argenx website, accessible at argenx.com/investors. Additionally, a replay of the webcast will be accessible for approximately 90 days following the live event, providing ample opportunity for stakeholders to catch up on the proceedings.

Argenx is dedicated to enhancing the quality of life for individuals afflicted with severe autoimmune diseases. Through its Immunology Innovation Program (IIP), the company collaborates with top-tier academic researchers to convert groundbreaking discoveries in immunology into a robust portfolio of innovative antibody-based treatments. One of the company's significant achievements includes the development and commercialization of the first approved neonatal Fc receptor (FcRn) blocker. This therapeutic is available in several major markets globally, including the U.S., Japan, Israel, the EU, the UK, China, and Canada.

The company's flagship product, efgartigimod, is under evaluation for effectiveness in treating multiple serious autoimmune conditions. Beyond efgartigimod, argenx is also progressing several early-stage experimental medicines within its various therapeutic divisions, demonstrating its commitment to pioneering advancements in immunology.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!